decibel therapeutics hearing loss treatment

Decibel Therapeutics Gene Therapy Hearing Loss Treatment, DB-OTO, Receives Orphan Drug and Rare Pediatric Disease Designations from FDA

BOSTON, MASSACHUSSETTS — Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company’s lead gene therapy product candidate, DB-OTO, for the…

Read More
sensorion

Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as…

Read More
gene therapy hearing loss

New Stem Cell Technique May Help Treat Common Hereditary Deafness, Say Researchers

TOKYO, JAPAN — Researchers at Juntendo University report in the journal Human Molecular Genetics that a stem-cell technique may be used to develop a treatment of a common mutation-related type of deafness. The method involves reproducing cells occurring in the human inner ear where the researchers emphasize that ‘the pathological condition could be reproduced with…

Read More
decibel therapeutics catalent

Decibel Therapeutics and Catalent Partner to Develop Gene Therapy for Treatment of Congenital Hearing Loss

SOMERSET, NEW JERSEY & BOSTON, MASSACHUSSETTS — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, and Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders, today announced they have signed…

Read More
amplify genetic testing program auditory neuropathy

Decibel Therapeutics and Invitae Announce Launch of Amplify™ Genetic Testing Program

BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company dedicated to discovering and developing treatments to restore and improve hearing and balance, has announced a partnership with Invitae, a leading medical genetics company, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy.…

Read More
gene therapy hearing loss

Scientists Develop Innovative New Gene Therapy for Hearing Loss

A new study from Tel Aviv University (TAU) presents an innovative treatment for deafness, based on the delivery of genetic material into the cells of the inner ear. The genetic material “replaces” the genetic defect and enables the cells to continue functioning normally. The scientists were able to prevent the gradual deterioration of hearing in mice that…

Read More
decibel therapeutics hearing loss treatment

Decibel Therapeutics Announces Exclusive Licensing Agreements for Hearing Loss Gene Therapy Technology

BOSTON, MASSACHUSSETTS – Decibel Therapeutics, a clinical-stage biotechnology company developing novel restorative gene therapeutics to treat hearing loss and balance disorders, has announced exclusive license agreements with the University of Florida (UF) and the University of California, San Francisco (UCSF) for an adeno-associated virus (AAV) gene therapy technology designed to restore hearing to individuals with…

Read More
akouos gene therapy hearing loss treatment

Akouos Announces Expansion of Executive Team and Board of Directors

BOSTON, MASSACHUSSETTS — Akouos, Inc. (Nasdaq: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Alan Smith, Ph.D., as chief technology officer. In addition, the company announced that Saira Ramasastry has been appointed to its board of directors as…

Read More
akouos gene therapy hearing loss treatment

Akouos Files for $100M IPO to Accelerate Gene Therapy Hearing Loss Treatment Program

BOSTON, MASSACHUSSETTS – Akouos, a precision genetic medicine company developing gene therapies to restore and preserve hearing, has filed for an initial public offer (IPO) with the Securities and Exchange Commission, eyeing a $100M IPO. The filing comes barely 3 months after he company completed its Series B funding round, which raised $105M. The company’s…

Read More